Stocks in play: MYND Life Sciences

Announced it has entered into a non-binding memorandum of understanding to acquire all the issued and outstanding shares of Tidal Care Inc.o/a Tidal Psychedelics. Tidal is a vertically integrated psilocybin company with access to a $10 million leasehold facility purpose built for cannabis and mycelium cultivation. The primary goal of the combined entity is to provide MYND's highly sophisticated intellectual property portfolio with access to additional capital, and a diverse and an experienced management team to advance the Company's research and development initiatives. MYND Life Sciences shares C.MYND are trading unchanged at $0.13.

Read:

• Reducing the Risks of Adverse Reactions to Covid Vaccines May Also Reduce Hesitancy and Injuries

• Growing Plant-Based Protein Wholesalers Seizing Upon Market’s Appetite for Vegan Options

• Therapy Shake-Up Called for by Mental Health Experts Seeking Solutions for Mental Health Crisis

• Pharmacies and In-Clinic Testing Set to Remain as Covid-19 Numbers Shift into Post-Pandemic Phase

• Biotech Innovators Making Strides Towards Meeting Increased Demand for Breast Cancer Treatments